 Lisa Abuogi
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 58 | 2026 | 3079 | 9.290 |
Why?
| | Anti-HIV Agents | 27 | 2026 | 869 | 7.320 |
Why?
| | Infectious Disease Transmission, Vertical | 24 | 2026 | 187 | 6.290 |
Why?
| | Kenya | 37 | 2026 | 129 | 4.410 |
Why?
| | Pregnancy Complications, Infectious | 15 | 2026 | 422 | 3.350 |
Why?
| | Anti-Retroviral Agents | 10 | 2026 | 240 | 2.870 |
Why?
| | Viral Load | 14 | 2026 | 518 | 2.690 |
Why?
| | Breast Feeding | 10 | 2026 | 448 | 2.360 |
Why?
| | Sexual Partners | 8 | 2025 | 187 | 1.680 |
Why?
| | Sustained Virologic Response | 2 | 2026 | 46 | 1.510 |
Why?
| | Pregnancy | 30 | 2026 | 7180 | 1.410 |
Why?
| | Intimate Partner Violence | 4 | 2025 | 91 | 1.370 |
Why?
| | Medication Adherence | 7 | 2025 | 512 | 1.370 |
Why?
| | Qualitative Research | 8 | 2026 | 1659 | 1.360 |
Why?
| | Text Messaging | 4 | 2023 | 181 | 1.330 |
Why?
| | Infant | 29 | 2026 | 10022 | 1.200 |
Why?
| | Social Stigma | 10 | 2026 | 158 | 1.160 |
Why?
| | HIV-1 | 4 | 2026 | 895 | 1.130 |
Why?
| | Drug Monitoring | 2 | 2024 | 389 | 1.100 |
Why?
| | Mothers | 7 | 2022 | 774 | 1.090 |
Why?
| | Focus Groups | 5 | 2026 | 569 | 1.070 |
Why?
| | Peripartum Period | 2 | 2024 | 19 | 1.030 |
Why?
| | Social Support | 5 | 2024 | 649 | 1.000 |
Why?
| | Transition to Adult Care | 2 | 2026 | 94 | 1.000 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2025 | 244 | 0.940 |
Why?
| | Female | 56 | 2026 | 77976 | 0.900 |
Why?
| | Spouses | 4 | 2020 | 108 | 0.900 |
Why?
| | Prenatal Care | 4 | 2020 | 306 | 0.900 |
Why?
| | Postpartum Period | 8 | 2025 | 361 | 0.780 |
Why?
| | Young Adult | 21 | 2026 | 13990 | 0.780 |
Why?
| | Fathers | 1 | 2023 | 51 | 0.780 |
Why?
| | Peer Group | 2 | 2024 | 242 | 0.750 |
Why?
| | Patient Navigation | 1 | 2024 | 104 | 0.730 |
Why?
| | Humans | 64 | 2026 | 144261 | 0.720 |
Why?
| | Zambia | 5 | 2025 | 56 | 0.710 |
Why?
| | Drug Resistance, Viral | 4 | 2026 | 122 | 0.680 |
Why?
| | Interviews as Topic | 3 | 2024 | 898 | 0.670 |
Why?
| | Fertilization | 1 | 2021 | 44 | 0.660 |
Why?
| | Mentors | 3 | 2021 | 218 | 0.620 |
Why?
| | Adult | 31 | 2026 | 40262 | 0.600 |
Why?
| | Adolescent | 22 | 2026 | 22281 | 0.600 |
Why?
| | Male | 34 | 2026 | 72035 | 0.580 |
Why?
| | Infant, Newborn | 11 | 2026 | 6424 | 0.560 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2026 | 1705 | 0.560 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 287 | 0.550 |
Why?
| | Heterocyclic Compounds, 3-Ring | 3 | 2026 | 43 | 0.530 |
Why?
| | Motivation | 1 | 2022 | 605 | 0.530 |
Why?
| | Child | 23 | 2026 | 22537 | 0.520 |
Why?
| | Health Facilities | 2 | 2021 | 85 | 0.520 |
Why?
| | Health Facility Administration | 1 | 2017 | 7 | 0.510 |
Why?
| | Telemedicine | 2 | 2025 | 940 | 0.510 |
Why?
| | Community Health Services | 2 | 2019 | 232 | 0.500 |
Why?
| | Spouse Abuse | 1 | 2017 | 41 | 0.500 |
Why?
| | Truth Disclosure | 1 | 2017 | 48 | 0.500 |
Why?
| | Reminder Systems | 1 | 2018 | 141 | 0.490 |
Why?
| | Patient Dropouts | 1 | 2016 | 64 | 0.470 |
Why?
| | HIV Integrase Inhibitors | 2 | 2026 | 77 | 0.440 |
Why?
| | Health Resources | 1 | 2016 | 129 | 0.440 |
Why?
| | Treatment Failure | 4 | 2026 | 363 | 0.420 |
Why?
| | Tuberculosis | 2 | 2014 | 289 | 0.390 |
Why?
| | Point-of-Care Systems | 3 | 2023 | 187 | 0.370 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2026 | 1409 | 0.370 |
Why?
| | Patient Compliance | 1 | 2016 | 585 | 0.360 |
Why?
| | Prospective Studies | 6 | 2025 | 7970 | 0.340 |
Why?
| | Multicenter Studies as Topic | 2 | 2026 | 402 | 0.330 |
Why?
| | Colorado | 4 | 2025 | 4562 | 0.320 |
Why?
| | Patient Acceptance of Health Care | 3 | 2025 | 878 | 0.310 |
Why?
| | Child, Preschool | 10 | 2026 | 11774 | 0.300 |
Why?
| | Consultants | 2 | 2026 | 12 | 0.300 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1559 | 0.260 |
Why?
| | Lactation | 2 | 2026 | 192 | 0.250 |
Why?
| | Developing Countries | 2 | 2021 | 314 | 0.250 |
Why?
| | Case-Control Studies | 3 | 2018 | 3592 | 0.230 |
Why?
| | Viremia | 1 | 2026 | 158 | 0.220 |
Why?
| | Cross-Sectional Studies | 6 | 2026 | 5813 | 0.210 |
Why?
| | Retrospective Studies | 8 | 2024 | 17009 | 0.210 |
Why?
| | United States | 5 | 2026 | 15876 | 0.200 |
Why?
| | Intention | 1 | 2025 | 183 | 0.200 |
Why?
| | Risk Factors | 5 | 2025 | 10699 | 0.200 |
Why?
| | Infant Health | 1 | 2023 | 25 | 0.200 |
Why?
| | RNA, Viral | 2 | 2024 | 687 | 0.200 |
Why?
| | Dried Blood Spot Testing | 1 | 2024 | 126 | 0.200 |
Why?
| | Maternal Health | 1 | 2023 | 52 | 0.190 |
Why?
| | Prevalence | 3 | 2024 | 2815 | 0.190 |
Why?
| | Proportional Hazards Models | 4 | 2024 | 1322 | 0.190 |
Why?
| | CD4 Lymphocyte Count | 2 | 2024 | 274 | 0.190 |
Why?
| | DNA, Viral | 1 | 2024 | 358 | 0.180 |
Why?
| | Telephone | 1 | 2023 | 174 | 0.180 |
Why?
| | Oxazines | 3 | 2026 | 36 | 0.180 |
Why?
| | Drug Resistance | 1 | 2022 | 153 | 0.180 |
Why?
| | Sexual Behavior | 1 | 2025 | 484 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2025 | 1087 | 0.170 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 27 | 0.170 |
Why?
| | Emigrants and Immigrants | 1 | 2023 | 157 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2021 | 11643 | 0.160 |
Why?
| | Public Health Surveillance | 1 | 2021 | 83 | 0.160 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 37 | 0.160 |
Why?
| | Organophosphates | 1 | 2022 | 187 | 0.160 |
Why?
| | Reward | 1 | 2022 | 245 | 0.160 |
Why?
| | Mass Screening | 2 | 2020 | 1332 | 0.160 |
Why?
| | Pyridones | 3 | 2026 | 198 | 0.160 |
Why?
| | Patient Participation | 1 | 2023 | 429 | 0.150 |
Why?
| | Infant, Low Birth Weight | 1 | 2021 | 153 | 0.150 |
Why?
| | Pilot Projects | 1 | 2025 | 1867 | 0.150 |
Why?
| | Symptom Assessment | 1 | 2021 | 137 | 0.150 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2021 | 231 | 0.150 |
Why?
| | Students | 1 | 2025 | 661 | 0.150 |
Why?
| | Health Personnel | 2 | 2023 | 742 | 0.150 |
Why?
| | Adenine | 1 | 2022 | 339 | 0.150 |
Why?
| | Piperazines | 3 | 2026 | 380 | 0.150 |
Why?
| | Disclosure | 1 | 2019 | 85 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2021 | 416 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 727 | 0.140 |
Why?
| | Odds Ratio | 1 | 2021 | 1072 | 0.140 |
Why?
| | Ambulatory Care | 1 | 2023 | 597 | 0.140 |
Why?
| | Emotions | 1 | 2023 | 577 | 0.130 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 108 | 0.130 |
Why?
| | Pregnancy Outcome | 1 | 2021 | 476 | 0.130 |
Why?
| | Self Disclosure | 1 | 2017 | 62 | 0.130 |
Why?
| | HIV | 1 | 2018 | 248 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2026 | 6021 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1129 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 643 | 0.130 |
Why?
| | Decision Making | 1 | 2024 | 974 | 0.120 |
Why?
| | HIV Seropositivity | 1 | 2017 | 118 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1646 | 0.120 |
Why?
| | Marriage | 1 | 2017 | 122 | 0.120 |
Why?
| | Rural Population | 2 | 2017 | 648 | 0.110 |
Why?
| | Logistic Models | 2 | 2025 | 2104 | 0.110 |
Why?
| | Health Services Research | 1 | 2017 | 394 | 0.110 |
Why?
| | Hospitalization | 2 | 2023 | 2424 | 0.100 |
Why?
| | Attitude of Health Personnel | 2 | 2024 | 1182 | 0.100 |
Why?
| | Biomarkers | 2 | 2024 | 4254 | 0.100 |
Why?
| | Isoniazid | 1 | 2014 | 71 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2917 | 0.090 |
Why?
| | Cohort Studies | 3 | 2024 | 5935 | 0.090 |
Why?
| | Incidence | 2 | 2022 | 2870 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2014 | 215 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 940 | 0.090 |
Why?
| | Nasopharynx | 2 | 2022 | 73 | 0.090 |
Why?
| | Mutation | 1 | 2022 | 4085 | 0.080 |
Why?
| | Depression | 1 | 2020 | 1533 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4278 | 0.080 |
Why?
| | Time Factors | 1 | 2018 | 7155 | 0.060 |
Why?
| | Africa South of the Sahara | 1 | 2026 | 49 | 0.060 |
Why?
| | Lamivudine | 1 | 2026 | 65 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3637 | 0.060 |
Why?
| | Canada | 1 | 2026 | 428 | 0.050 |
Why?
| | Observation | 1 | 2024 | 54 | 0.050 |
Why?
| | Cerebrospinal Fluid | 1 | 2024 | 88 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 612 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2026 | 1044 | 0.050 |
Why?
| | Universities | 1 | 2025 | 451 | 0.050 |
Why?
| | North America | 1 | 2023 | 310 | 0.050 |
Why?
| | Point-of-Care Testing | 1 | 2022 | 35 | 0.050 |
Why?
| | Milk, Human | 1 | 2023 | 172 | 0.040 |
Why?
| | Africa, Northern | 1 | 2021 | 4 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2022 | 169 | 0.040 |
Why?
| | Oropharynx | 1 | 2020 | 46 | 0.040 |
Why?
| | Professional-Patient Relations | 1 | 2022 | 153 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1833 | 0.040 |
Why?
| | Trust | 1 | 2022 | 151 | 0.040 |
Why?
| | Income | 1 | 2021 | 199 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 197 | 0.040 |
Why?
| | Family Characteristics | 1 | 2020 | 196 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2026 | 2926 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 451 | 0.030 |
Why?
| | Mental Health | 1 | 2025 | 776 | 0.030 |
Why?
| | House Calls | 1 | 2019 | 154 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2018 | 160 | 0.030 |
Why?
| | Gene Expression | 1 | 2022 | 1487 | 0.030 |
Why?
| | Middle Aged | 3 | 2026 | 35762 | 0.030 |
Why?
| | Poverty | 1 | 2021 | 523 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2020 | 555 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1682 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 946 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3403 | 0.020 |
Why?
| | Aged | 1 | 2022 | 25850 | 0.010 |
Why?
|
|
Abuogi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|